GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » Median PS Value

Guardant Health (Guardant Health) Median PS Value

: $0.00 (As of Today)
View and export this data going back to 2018. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.037. Guardant Health's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-16), Guardant Health's share price is $17.065. Guardant Health's Median PS Value is $0.00. Therefore, Guardant Health's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Guardant Health's Median PS Value or its related term are showing as below:

GH's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.845
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Guardant Health Median PS Value Historical Data

The historical data trend for Guardant Health's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Premium Member Only Premium Member Only Premium Member Only - - - - -

Guardant Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Diagnostics & Research subindustry, Guardant Health's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health Price-to-Median-PS-Value Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Guardant Health's Price-to-Median-PS-Value falls into.



Guardant Health Median PS Value Calculation

Guardant Health's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=5.037*0
=0.00

10-Year Median PS Ratio is 0.
Guardant Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.037.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardant Health  (NAS:GH) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Guardant Health's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=17.065/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guardant Health Median PS Value Related Terms

Thank you for viewing the detailed overview of Guardant Health's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health (Guardant Health) Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Executives
Meghan V. Joyce director THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Kumud Kalia officer: Chief Information Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Ines Dahne-steuber officer: Chief Operating Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova officer: Chief Technology Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy director, officer: Chief Executive Officer 2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz director, officer: Chairman, President and COO 18 ISABELLA AVENUE, ATHERTON CA 94027
Musa Tariq director 3100 HANOVER STREET, PALO ALTO CA 94304
Amelia Merrill officer: SVP, People 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman director 2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Chris Freeman officer: Chief Commercial Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Bahija Jallal director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Vijaya Gadde director C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103